Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study

Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study

Background: Although transcranial magnetic stimulation (TMS) can be an effective acute antidepressant treatment, few studies systematically examine persistence of benefit. Objective: We assessed the durability of antidepressant effect after acute response to TMS in patients with major depressive dis...

Full description

Bibliographic Details
Main Authors: Philip G. Janicak, Ziad Nahas, Sarah H. Lisanby, H. Brent Solvason, Shirlene M. Sampson, William M. McDonald, Lauren B. Marangell, Peter Rosenquist, W. Vaughn McCall, James Kimball, John P. O’Reardon, Colleen Loo, Mustafa H. Husain, Andrew Krystal, William Gilmer, Sheila M. Dowd, Mark A. Demitrack, Alan F. Schatzberg
Format: Article
Language:English
Published: Elsevier 2010-10-01
Series:Brain Stimulation
Subjects:
antidepressant
clinical trial
major depression
maintenance of effect
TMS
treatment resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S1935861X10001105

Internet

http://www.sciencedirect.com/science/article/pii/S1935861X10001105

Similar Items